Postherpetic Neuralgia ( PHN )
12
1
1
7
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 12 trials
100.0%
+13.5% vs benchmark
25%
3 trials in Phase 3/4
29%
2 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (12)
Intradermal Exosomes, Platelet-Rich Plasma, and Steroids for Post-Herpetic Neuralgia
Postherpetic Neuralgia After Herpes Zoster and Incident Dementia Risk
Predictors of Success After Intercostal Nerve Radiofrequency Treatment for Intercostal Neuralgia
Pulsed Radiofrequency in Post Herptic Neuralgia
Electroacupuncture for PHN: Efficacy and Biomarker Evaluation in a Multicenter, Randomized, Sham-Controlled Trial Protocol
Early Screening Markers of Herpes Zoster Neuralgia
Effectiveness of Warm Acupuncture in Patients with Postherpetic Neuralgia
Pregabalin Treatment Of Peripheral Neuropathic Pain Associated With Diabetic Peripheral NeP (DPN), Postherpetic Neuralgia (PHN), HIV-related NeP (HIV), and Chemotherapy Induced NeP
Pregabalin for Treatment of Patients With Postherpetic Neuralgia (PHN)
A Study to Compare QUTENZA With Pregabalin for the Treatment of Peripheral Neuropathic Pain (PNP) After 8 Weeks of Treatment
A Study Into Pain Relief Given by ASP8477 for Peripheral Neuropathic Pain (Either Post-herpetic Neuralgia or Painful Diabetic Peripheral Neuropathy) and Its Safety
Crossover Post-herpetic Neuralgia (PHN)